We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Lupin has announced that it has received approval from the US health regulator to market its generic Gabapentin tablets used for treatment of postherpetic neuralgia in the American market.